🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

106 results for “injectable” Clear

  1. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  3. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  4. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  5. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial

  6. CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  7. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  8. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  9. ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, MELPHALAN, VINCRISTINE TEVA 1 mg/ml, solution injectable, ALKERAN 50 mg poudre et solvant pour solution pour perfusion Melphalan

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  10. EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  11. Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  12. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  13. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  14. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

  15. IPN10200 placebo, Powder for solution for injection, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable

    Ipsen

    Upper limb spasticity after stroke or traumatic brain injury

    phase 2 small molecule active

    1 trial

  16. Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  17. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENDOXAN 1000 mg, poudre pour solution injectable, EPIRUBICINE MEDAC 2 mg/ml, solution pour perfusion, PACLITAXEL KABI 6 mg/ml, solution à diluer pour perfusion.

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun

    Philogen S.p.A.

    Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy

    phase 2 small molecule active

    1 trial

  20. LEVOFOLINATE DE CALCIUM ZENTIVA 10 mg/ml, solution injectable (IM/IV), Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Bemarituzumab, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ACCORD 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  21. Lidocaine Hydrochloride, Injectable

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Postoperative Chronic Pain

    phase 2 small molecule active

    1 trial

  22. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  23. ONCOVIN 1 mg, solution injectable, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, ENDOXAN 1000 mg, poudre pour solution injectable, ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, TEPADINA 15 mg powder for concentrate for solution for infusion, THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  24. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources